<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408183</url>
  </required_header>
  <id_info>
    <org_study_id>T2R-002</org_study_id>
    <nct_id>NCT04408183</nct_id>
  </id_info>
  <brief_title>GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel</brief_title>
  <official_title>Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection in Healthcare Personnel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will evaluate the safety, tolerability and effectiveness of topical
      GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized, placebo-controlled, double-blind study will assess whether topical
      GLS-1200 applied via nasal spray atomizer is well-tolerated and can reduce the incidence of
      confirmed SARS-CoV-2 infection. Subjects will be randomized to either the GLS-1200 or placebo
      group in a 2:1 ratio with a target enrollment of 225 subjects. Subjects will self-administer
      study drug three times daily for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group</measure>
    <time_frame>4 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome.</measure>
    <time_frame>4 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>SARS-CoV 2</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>GLS-1200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mL of GLS-1200 per nostril, TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 %Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 mL of 0.9% Saline per nostril, TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-1200</intervention_name>
    <description>GLS-1200 is given as a nasal spray using an atomizer</description>
    <arm_group_label>GLS-1200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is given as a nasal spray using an atomizer</description>
    <arm_group_label>0.9 %Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Able to provide informed consent

          -  Able and willing to comply with study procedures

          -  Adult healthcare professional

        Exclusion Criteria:

          -  Know allergy to quinine, quinidine, or mefloquine

          -  Confirmed prior positive test for SARS-CoV-2

          -  Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>484-965-9147</phone>
    <email>jmaslow@geneonels-us.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Project Manager</last_name>
    <email>cremigio@geneonels-us.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupa Chowdary</last_name>
      <phone>215-573-5073</phone>
      <email>Rupa.Chowdary@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

